Back to top
more

Catalent (CTLT)

(Delayed Data from NYSE)

$55.92 USD

55.92
2,846,383

+0.12 (0.22%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $55.90 -0.02 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 3.57% and 97.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Stock Jumps 6.8%: Will It Continue to Soar?

by Zacks Equity Research

Catalent (CTLT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Catalent (CTLT) Q3 Earnings Expected to Decline

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent (CTLT) Declines on Profit Warnings and CFO Exit

by Zacks Equity Research

Catalent (CTLT) issues a profit warning for third-quarter fiscal 2023 amid supply chain disruptions and operational challenges. It also announces the departure of its CFO.

Here's Why You Should Retain Catalent (CTLT) Stock for Now

by Zacks Equity Research

Catalent's (CTLT) product and service launches, and a slew of strategic deals raise optimism about the stock.

Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials

by Zacks Equity Research

Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.

Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses

by Zacks Equity Research

Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.

Catalent (CTLT) Inks Deal for New & Effective Drug Delivery

by Zacks Equity Research

Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.

Zoetis (ZTS) Down 6.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalent's (CTLT) Tie-Up to Accelerate Clinical Trial Timelines

by Zacks Equity Research

Catalent's (CTLT) latest collaboration is expected to leverage multiple services that reduce drug development timelines.

Here's Why You Should Retain Catalent (CTLT) Stock for Now

by Zacks Equity Research

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.

Compared to Estimates, Catalent (CTLT) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Catalent (CTLT) Surges on Rumors of Acquisition by Danaher

by Zacks Equity Research

Catalent (CTLT) shares gain significantly, following a Bloomberg report about a potential acquisition of the CDMO company by Danaher, a life sciences company.

Catalent (CTLT) Q2 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Catalent (CTLT) records lower revenues in both segments in its second-quarter fiscal 2023, resulting in overall soft performance.

Catalent (CTLT) Misses Q2 Earnings Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of -6.94% and 2.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Catalent (CTLT)

by Zacks Equity Research

Catalent (CTLT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q2 results are likely to have been driven by robust segmental performances.

Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Taro Pharmaceutical (TARO) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Taro (TARO) delivered earnings and revenue surprises of -78.16% and 14.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology

by Zacks Equity Research

Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Why Is Jazz (JAZZ) Up 0.1% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Theravance Bio (TBPH) Up 1.6% Since Last Earnings Report?

by Zacks Equity Research

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalent (CTLT) Expands Facility Capabilities in Shanghai

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in the clinical trials space in its Asia-Pacific Clinical Supply Services network.